These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37616532)

  • 21. The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients.
    vanDooren-Greebe RJ; Kuijpers AL; Buijs WC; Kniest PH; Corstens FH; Nagengast FM; de Boo T; Willems JL; Duller P; van de Kerkhof PC
    Br J Dermatol; 1996 Mar; 134(3):481-7. PubMed ID: 8731673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of folic acid supplementation in psoriasis patients receiving methotrexate: a survey in the United Kingdom.
    Kirby B; Lyon CC; Griffiths CE; Chalmers RJ
    Clin Exp Dermatol; 2000 Jun; 25(4):265-8. PubMed ID: 10971481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum type III procollagen peptide, dynamic liver function tests and hepatic fibrosis in psoriatic patients receiving methotrexate.
    Mitchell D; Smith A; Rowan B; Warnes TW; Haboubi NY; Lucas SB; Chalmers RJ
    Br J Dermatol; 1990 Jan; 122(1):1-7. PubMed ID: 2297495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients.
    van Swelm RP; Laarakkers CM; Kooijmans-Otero M; de Jong EM; Masereeuw R; Russel FG
    Toxicol Lett; 2013 Aug; 221(3):219-24. PubMed ID: 23830989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validity of noninvasive markers of methotrexate-induced hepatotoxicity: a retrospective cohort study.
    Martyn-Simmons CL; Rosenberg WM; Cross R; Wong T; Smith CH; Barker JN
    Br J Dermatol; 2014 Aug; 171(2):267-73. PubMed ID: 24942271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists.
    Mahé E; Beauchet A; Hadj-Rabia S; Mazereeuw-Hautier J; Mallet S; Phan A; Severino-Freire M; Boralevi F; Aubert H; Barthélémy H; Girard C; Martin L; Piram M; Barbarot S; Balguerie X; Zitouni J; Phan C; Di Lernia V;
    Dermatol Ther; 2022 Nov; 35(11):e15828. PubMed ID: 36107157
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Considerable variation among Iranian dermatologists in the dosing and monitoring of methotrexate for treating psoriasis.
    Zargari O; Hejazi S; Shahidi-Dadras M; Younespour S; Robati R; Firooz A; Toosi P; Feldman SR
    Int J Dermatol; 2014 Mar; 53(3):385-9. PubMed ID: 24134730
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.
    Montaudié H; Sbidian E; Paul C; Maza A; Gallini A; Aractingi S; Aubin F; Bachelez H; Cribier B; Joly P; Jullien D; Le Maître M; Misery L; Richard MA; Ortonne JP
    J Eur Acad Dermatol Venereol; 2011 May; 25 Suppl 2():12-8. PubMed ID: 21388454
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients.
    Wan J; Abuabara K; Troxel AB; Shin DB; Van Voorhees AS; Bebo BF; Krueger GG; Callis Duffin K; Gelfand JM
    J Am Acad Dermatol; 2012 Mar; 66(3):376-86. PubMed ID: 21856040
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
    Alabas OA; Mason KJ; Yiu ZZN; Warren RB; Lunt M; Smith CH; Griffiths CEM;
    Br J Dermatol; 2023 Aug; 189(3):271-278. PubMed ID: 37226927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness and cost-benefit analysis of using methotrexate vs Goeckerman therapy for psoriasis. A pilot study.
    Chen S; Shaheen A; Garber A
    Arch Dermatol; 1998 Dec; 134(12):1602-8. PubMed ID: 9875201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methotrexate: improving safety profile.
    Grills C; Burge S
    Australas J Dermatol; 2006 Aug; 47(3):178-81. PubMed ID: 16866998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients.
    Boffa MJ; Smith A; Chalmers RJ; Mitchell DM; Rowan B; Warnes TW; Shomaf M; Haboubi NY
    Br J Dermatol; 1996 Oct; 135(4):538-44. PubMed ID: 8915142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidelines for management of patients with psoriasis. Workshop of the Research Unit of the Royal College of Physicians of London; Department of Dermatology, University of Glasgow; British Association of Dermatologists.
    BMJ; 1991 Oct; 303(6806):829-35. PubMed ID: 1932977
    [No Abstract]   [Full Text] [Related]  

  • 35. Real world prescription trends of methotrexate for psoriasis in Argentina: results of a national survey.
    Mazzuoccolo LD; Luna PC; Marciano S; Castro Perez GA; Marchesi C; Nocito MJ; Martin Koller V; Lorenzo J; Koch C; Echeverria CM
    J Dermatolog Treat; 2017 Nov; 28(7):631-634. PubMed ID: 28489482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methotrexate in psoriasis. A brief review of indications, usage, and complications of methotrexate therapy.
    Hanno R; Gruber GG; Owen LG; Callen JP
    J Am Acad Dermatol; 1980 Feb; 2(2):171-4. PubMed ID: 7364974
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The treatment of severe psoriasis. A national survey.
    Peckham PE; Weinstein GD; McCullough JL
    Arch Dermatol; 1987 Oct; 123(10):1303-7. PubMed ID: 3662561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR.
    Alabas OA; Mason KJ; Yiu ZZN; Hampton PJ; Reynolds NJ; Owen CM; Bewley A; Laws PM; Warren RB; Lunt M; Smith CH; Griffiths CEM;
    Br J Dermatol; 2023 Apr; 188(5):618-627. PubMed ID: 36763783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methotrexate for psoriasis in the era of biological therapy.
    Warren RB; Chalmers RJ; Griffiths CE; Menter A
    Clin Exp Dermatol; 2008 Aug; 33(5):551-4. PubMed ID: 18801095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Palmoplantar pustular psoriasis following initiation of a beta-blocker: disease control with low-dose methotrexate.
    Stanford CW; Kollipara R; Melookaran AM; Hall JC
    Cutis; 2014 Sep; 94(3):153-5. PubMed ID: 25279477
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.